A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Trial Profile

A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2018

At a glance

  • Drugs DEBIO 1562 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 17 Feb 2018 Results assessing safety, pharmacokinetics and preliminary activity of IMGN 529 in a dose-finding cohort of patients with relapsed or refractory B-cell NHL, were published in the Investigational New Drugs.
    • 24 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 03 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top